PSMA-617

Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals
Endpoints
Wed, 10/14/20 - 10:51 am
Versant Ventures
PSMA-617
radiopharmaceuticals
prostate cancer
Novartis
Rayze Bio
venBio
3 Drug Stocks That Soared This Week
Motley Fool
Sun, 10/8/17 - 11:26 am
Endocyte
PSMA-617
MannKind
Afrezza
Mylan Labs
generics
Teva Pharmaceutical
Endocyte Adds Phase 3-Ready Prostate Cancer Drug with ABX Deal
Xconomy
Mon, 10/2/17 - 11:07 am
Endocyte
prostate cancer
ABX
PSMA-617